Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer
Open accessAbstract
Purpose: Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial and preclinical PC models. Patients and Methods: Patients with PC not amenable to curative therapy who had received no prior therapy for metastatic disease and had Karnofsky performance score ≥ 80 were enrolled. Patients were randomly assigned in a one-to-one ratio to GV or GP. The primary end point was progression-free-survival (PFS). Exploratory correlative studies included serial SHH serum levels and contrast perfusion computed tomography imaging. To further investigate putative biologic mechanisms of SMO inhibition, two autochthonous pancreatic cancer models (Kras G12D; p16/p19 fl/fl; Pdx1-Cre and Kras G12D; p53 R270H/wt; Pdx1-Cre) were studied. Results: No safety issues were identified in the phase Ib portion (n = 7), and the phase II study enrolled 106 evaluable patients (n = 53 in each arm). Median PFS was 4.0 and 2.5 months for GV and GP arms, respectively (95% CI, 2.5 to 5.3 and 1.9 to 3.8, respectively; adjusted hazard ratio, 0.81; 95% CI, 0.54 to 1.21; P = .30). Median overall survival (OS) was 6.9 and 6.1 months for GV and GP arms, respectively (95% CI, 5.8 to 8.0 and 5.0 to 8.0, respectively; adjusted hazard ratio, 1.04; 95% CI, 0.69 to 1.58; P = .84). Response rates were not significantly different. There were no significant associations between correlative markers and overall response rate, PFS, or OS. Preclinical trials revealed no significant differences with vismodegib in drug delivery, tumor growth rate, or OS in either model. Conclusion: The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several recent encouraging clinical results in PDAC followed rigorous preclinical work in syngeneic and autochthonous models that preceded and shaped the trial design.
“Many of the recent promising clinical signals in PDAC have arisen through rigorous preclinical analyses in syngeneic and autochthonous models that predated the trial and informed its design288.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [288]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825 · see citing works
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895 · see citing works
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · see citing works
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y., Gysin, S., Castillo, C. F. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,479 · see citing works
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Hoff, D. D. V., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109 · see citing works
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,017 · see citing works
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T. T.-L., Tian, H., Ahn, C. P., Marshall, D. C. L., Fu, L., Januario, T., Kallop, D. Y., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961 · see citing works
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848 · see citing works
Self-citationCutsem, E. V., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Laethem, J. V., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J. G. C. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 651 · see citing works
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632 · see citing works
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2899 · Cited by 567 · see citing works
LoRusso, P. M., Rudin, C. M., Reddy, J. C., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Chang, I., Darbonne, W. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2745 · Cited by 543 · see citing works
Romer, J. T., Kimura, H., Magdaleno, S. M., Sasai, K., Fuller, C. E., Baines, H., Connelly, M., Stewart, C. F., Gould, S. E., Rubin, L. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.019 · Cited by 521 · see citing works
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffrey, T. C., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 520 · see citing works
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502 · see citing works
Hruban, R., Adsay, N., Albores-saavedra, J., Anver, M., Biankin, A., Boivin, G. P., Furth, E., Furukawa, T., Klein, A., Klimstra, D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2168 · Cited by 411 · see citing works
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Tian, H., Callahan, C. A., DuPree, K., Darbonne, W. C., Ahn, C. P., Scales, S. J., & de Sauvage, F. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813203106 · Cited by 404 · see citing works
Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Letourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 402 · see citing works
Self-citationGDC-0449—A potent inhibitor of the hedgehog pathway
Robarge, K. D., Brunton, S. A., Castanedo, G. M., Cui, Y., Dina, M. S., Goldsmith, R. A., Gould, S. E., Guichert, O., Gunzner, J. L., Halladay, J. S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.049 · Cited by 387 · see citing works
Dijkgraaf, G. J. P., Alicke, B., Weinmann, L., Januario, T., West, K. A., Modrusan, Z. D., Burdick, D., Goldsmith, R. A., Robarge, K. D., Sutherlin, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2876 · Cited by 365 · see citing works
Kim, E. J.-H., Sahai, V., Abel, E. V., Griffith, K. A., Greenson, J. K., Takebe, N., Khan, G. N., Blau, J., Craig, R. A., Balis, U. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1269 · Cited by 306 · see citing works
Self-citationFeldmann, G., Fendrich, V., McGovern, K., Bedja, D., Bisht, S., Alvarez, H., Koorstra, J.-B. M., Habbe, N., Karikari, C. A., Mullendore, M. E., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0573 · Cited by 275 · see citing works
Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)
Tremblay, M. R., Lescarbeau, A., Grogan, M. J., Tan, E., Lin, G., Austad, B. C., Yu, L.-C., Behnke, M. L., Nair, S. J., Hagel, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900305z · Cited by 252 · see citing works
Prasad, N. B., Biankin, A. V., Fukushima, N., Maitra, A., Dhara, S., ELKAHLOUN, A. G., Hruban, R. H., Goggins, M., & Leach, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1413 · Cited by 240 · see citing works
Growth inhibition of polyoma transformed cells by contact with static normal fibroblasts
Stoker, M. G. P., Shearer, M., & O'Neill, C. H. (1966) · Journal of Cell Science · doi:10.1242/jcs.1.3.297 · Cited by 216 · see citing works
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215 · see citing works
Paracrine Hedgehog Signaling in Cancer
Theunissen, J.-W. F., & de Sauvage, F. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0756 · Cited by 201 · see citing works
Wang, Y., Zhou, Z., Walsh, C. T., & McMahon, A. P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812110106 · Cited by 199 · see citing works
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer
Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R. M., Mullendore, M. E., Karikari, C. A., Bardeesy, N. M., et al. (2008) · Gut · doi:10.1136/gut.2007.148189 · Cited by 193 · see citing works
Walter, K., Omura, N., Hong, S., Griffith, M., Vincent, A., Borges, M. W., & Goggins, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1913 · Cited by 172 · see citing works
Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
Jimeno, A., Weiss, G. J., Miller, W. H., Gettinger, S. N., Eigl, B. J., Chang, A. L. S., Dunbar, J., Devens, S., Faia, K., Skliris, G. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3654 · Cited by 171 · see citing works
Functional computed tomography in oncology
Miles, K. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00386-6 · Cited by 152 · see citing works
Catenacci, D. V. T. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144 · see citing works
Self-citationDotto, G. P., Weinberg, R. A., & Ariza, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6389 · Cited by 136 · see citing works
Chen, W., Tang, T. T.-L., Eastham-Anderson, J., Dunlap, D. Y., Alicke, B., Nannini, M., Gould, S. E., Yauch, R. L., Modrusan, Z. D., DuPree, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017945108 · Cited by 119 · see citing works
Hedgehog signaling and therapeutics in pancreatic cancer
Kelleher, F. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq280 · Cited by 115 · see citing works
The Hedgehog Pathway and Pancreatic Cancer
Hidalgo, M. M., & Maitra, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmcibr0905857 · Cited by 110 · see citing works
Kandel, S. M., Kloeters, C., Meyer, H., Hein, P. A., Hilbig, A., & Rogalla, P. (2009) · European Radiology · doi:10.1007/s00330-009-1453-z · Cited by 107 · see citing works
The dawn of hedgehog inhibitors: Vismodegib
Selvarajan, S., Melvin, G., Kumar, S. S., & Dkhar, S. A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.107628 · Cited by 86 · see citing works
Discovery and preclinical development of vismodegib
Gould, S. E., Low, J. A., Marsters, J. C., Robarge, K. D., Rubin, L. L., de Sauvage, F. J., Sutherlin, D. P., Wong, H., & Yauch, R. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.920816 · Cited by 72 · see citing works
Hattori, Y., Gabata, T., Matsui, O., Mochizuki, K., Kitagawa, H., Kayahara, M., Ohta, T., & Nakanuma, Y. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3114 · Cited by 58 · see citing works
Wong, H., Chen, J. Z., Chou, B., Halladay, J. S., Kenny, J. R., La, H., Marsters, J. C., Plise, E. G., Rudewicz, P. J., Robarge, K. D., et al. (2009) · Xenobiotica · doi:10.3109/00498250903180289 · Cited by 56 · see citing works
Jesus‐Acosta, A. D., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Maitra, A., Rasheed, Z. A., Zheng, L., Rajeshkumar, N. V., Le, D. T., Hoering, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.257 · Cited by 53 · see citing works
Catenacci, D. V. T., Bahary, N., Nattam, S. R., Marsh, R., Wallace, J. A., Rajdev, L. N., Cohen, D. J., Sleckman, B. G., Lenz, H., Stiff, P. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4012 · Cited by 39 · see citing works
Self-citationAbe, H., Murakami, T., Kubota, M., Kim, T., Hori, M., Kudo, M., Hashimoto, K., Nakamori, S., Dono, K., Tomoda, K., et al. (2005) · PubMed · Cited by 35 · see citing works
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer
Xu, F.-G., Ma, Q., & Wang, Z. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.014 · Cited by 29 · see citing works
Yuki, Y., Hattori, Toshifumi, Gabata, Osamu, Matsui, Kentaro, Mochizuki, Hirohisa, Kitagawa, et al. (2009) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 28 · see citing works
Plasma Shh Levels Reduced in Pancreatic Cancer Patients
Zaatari, M. E., Daignault, S. D., Tessier, A., Kelsey, G., Travnikar, L. A., Cantu, E. F., Lee, J., Plonka, C. M., Simeone, D. M., Anderson, M. A., et al. (2012) · Pancreas · doi:10.1097/mpa.0b013e31824a0eeb · Cited by 15 · see citing works
Flagged first, then by citations
1 of the 55 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241 · see citing works
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982 · see citing works
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,920 · see citing works
Self-citationPancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265 · see citing works
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230 · see citing works
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,295 · see citing works
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026 · see citing works
Cox, T. R. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 989 · see citing works
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950 · see citing works
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 875 · see citing works
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735 · see citing works
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 601 · see citing works
Cancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 596 · see citing works
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Rimkus, T. K., Carpenter, R. L., Qasem, S. A., Chan, M. D., & Lo, H. (2016) · Cancers · doi:10.3390/cancers8020022 · Cited by 580 · see citing works
Targeting Cancer Stemness in the Clinic: From Hype to Hope
Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517 · see citing works
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502 · see citing works
Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., Hitre, E., Hammel, P., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00590 · Cited by 499 · see citing works
Self-citationFord, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P., Wood, O., Machado, M., Lopez, M.-A., Ganesan, A.-P., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3158 · Cited by 411 · see citing works
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations
Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., Chin, L., Filliol, A., Wen, W., Song, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.012 · Cited by 416 · see citing works
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Thomas, D., & Radhakrishnan, P. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0927-5 · Cited by 399 · see citing works
Sleeboom, J. J. F., van Tienderen, G. S., Schenke‐Layland, K., van der Laan, L. J. W., Khalil, A., & Verstegen, M. M. A. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3840 · Cited by 391 · see citing works
Metastasis-Initiating Cells and Ecosystems
Massagué, J., & Ganesh, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0010 · Cited by 372 · see citing works
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neeße, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2018) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 348 · see citing works
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity
Hutton, C., Heider, F., Blanco-Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S., Paulus-Hock, V., Watt, D., Steele, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.017 · Cited by 337 · see citing works
Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01295 · Cited by 336 · see citing works
Han, X., Li, Y., Xu, Y., Zhao, X., Zhang, Y., Yang, X., Wang, Y., Zhao, R., Anderson, G. J., Zhao, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05906-x · Cited by 339 · see citing works
Microenvironmental Determinants of Pancreatic Cancer
Heßmann, E., Buchholz, S., Demir, İ. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neeße, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 329 · see citing works
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 322 · see citing works
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Pereira, B., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 309 · see citing works
Hedgehog Signaling: From Basic Biology to Cancer Therapy
Wu, F., Zhang, Y., Sun, B., McMahon, A. P., & Wang, Y. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.02.010 · Cited by 304 · see citing works
Biomarkers for cancer-associated fibroblasts
Han, C., Liu, T., & Yin, R. H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00245-w · Cited by 302 · see citing works
Neuzillet, C., Tijeras‐Raballand, A., Ragulan, C., Cros, J. F., Patil, Y., Martinet, M., Erkan, M., Kleeff, J. H., Wilson, J. S., Apte, M. V., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5224 · Cited by 296 · see citing works
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12392 · Cited by 292 · see citing works
Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
Zhao, J., Wen, X., Li, T. X., Li, T., Xu, C., Wen, X., Melancon, M. P., Gupta, S. K., Shen, B., Peng, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08782-1 · Cited by 272 · see citing works
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A., Noeen, S., Kattermann, K. E., Greenberg, M., Williams, A. F., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.003 · Cited by 260 · see citing works
Hedgehog signaling in tissue homeostasis, cancers and targeted therapies
Jing, J., Wu, Z., Wang, J., Luo, G., Lin, H., Fan, Y., & Zhou, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01559-5 · Cited by 261 · see citing works
Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 253 · see citing works
Liu, Y., Sinjab, A. F., Min, J., Han, G., Paradiso, F., Zhang, Y., Wang, R., Pei, G., Dai, Y., Liu, Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.004 · Cited by 249 · see citing works
The double edge sword of fibrosis in cancer
Chandler, C., Liu, T., Buckanovich, R. J., & Coffman, L. G. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.006 · Cited by 248 · see citing works
Cancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 252 · see citing works
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 239 · see citing works
Ko, A. H., LoConte, N. K., Tempero, M. A., Walker, E. J., Kelley, R. K., Lewis, S., Chang, W., Kantoff, E., Vannier, M. W., Catenacci, D. V. T., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000458 · Cited by 223 · see citing works
Self-citationLi, N., Kaur, P., Bunnag, N., Suresh, J., Sung, I. C. H., Tan, Q. H., Gruber, J., & Tolwinski, N. S. (2019) · Cells · doi:10.3390/cells8080826 · Cited by 219 · see citing works
Hedgehog signaling mechanism and role in cancer
Jiang, J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.003 · Cited by 220 · see citing works
Cancer-associated fibroblasts—heroes or villains?
Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0509-3 · Cited by 212 · see citing works
Engineering photodynamics for treatment, priming and imaging
Obaid, G., Celli, J. P., Broekgaarden, M., Bulin, A., Uusimaa, P., Pogue, B. W., Hasan, T. G., & Huang, H. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00196-z · Cited by 223 · see citing works
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 211 · see citing works
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
Purcell, J. W., Tanlimco, S. G., Hickson, J. A., Fox, M., Sho, M., Durkin, L. M., Uziel, T., Powers, R., Foster, K., McGonigal, T. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0327 · Cited by 207 · see citing works
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 203 · see citing works
Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells
Sari, I. N., Phi, L. T. H., Jun, N., Wijaya, Y. T., Lee, S., & Kwon, H. Y. (2018) · Cells · doi:10.3390/cells7110208 · Cited by 204 · see citing works
The challenge of targeting cancer stem cells to halt metastasis.
Agliano, A., Calvo, A., & Box, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.003 · Cited by 188 · see citing works
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx121 · Cited by 195 · see citing works
Targeting CAFs to overcome anticancer therapeutic resistance
Saw, P. E., Chen, J., & Song, E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 198 · see citing works
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P. B., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 201 · see citing works
Neuzillet, C., Gaujoux, S., Williet, N., Bachet, J., Bauguion, L., Durand, L. C., Conroy, T., Dahan, L., Gilabert, M., Huguet, F., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.008 · Cited by 197 · see citing works
The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
Sun, Q., Zhang, B., Hu, Q., Qin, Y., Xu, W., Liu, W., Yu, X., & Xu, J. (2018) · Theranostics · doi:10.7150/thno.26546 · Cited by 192 · see citing works
Knudsen, E. S., Vail, P. J., Balaji, U., Ngo, H., Botros, I. W., Makarov, V., Riaz, N., Balachandran, V. P., Leach, S. D., Thompson, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0162 · Cited by 191 · see citing works
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 198 · see citing works
Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer
Geng, X., Chen, H., Zhao, L., Hu, J., Yang, W., Li, G., Cheng, C., Zhao, Z., Zhang, T., Li, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655152 · Cited by 188 · see citing works
Datta, J., Dai, X., Bianchi, A., Silva, I. D. C., Mehra, S., Garrido, V. T., Lamichhane, P., Singh, S. P., Zhou, Z., Dosch, A. R., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2022.07.076 · Cited by 182 · see citing works
Emerging agents that target signaling pathways in cancer stem cells
Yang, Y., Li, X., Wang, T., Guo, Q., Xi, T., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00901-6 · Cited by 177 · see citing works
Jesus‐Acosta, A. D., Sugar, E. A., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Rasheed, Z. A., Zheng, L., Begum, A., Anders, R. A., Maitra, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 176 · see citing works
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer HeterogeneityPreprint
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 172 · see citing works
Liu, H., Kiseleva, A. A., & Golemis, E. A. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0023-6 · Cited by 173 · see citing works
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 163 · see citing works
Xie, Y., Yu, H., Wang, Y., Sleightholm, R. L., Prajapati, D. R., Bader, J., Yu, A., Tang, W., Jaramillo, L., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b03978 · Cited by 159 · see citing works
Liang, C., Shi, S., Meng, Q., Liang, D., Ji, S., Zhang, B., Qin, Y., Xu, J., Ni, Q., & Yu, X. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.255 · Cited by 160 · see citing works
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Menon, H., Ramapriyan, R., Cushman, T. R., Verma, V., Kim, H. H., Schoenhals, J. E., Atalar, S. C., Selek, U., Chun, S. G., Chang, J. Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00193 · Cited by 156 · see citing works
Zhan, H., Zhou, B., Cheng, Y., Xu, J., Wang, L., Zhang, G., & Hu, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.041 · Cited by 154 · see citing works
Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J., & Provenzano, P. P. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1334 · Cited by 153 · see citing works
Immunotherapy for pancreatic cancer: Barriers and breakthroughs
Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12176 · Cited by 150 · see citing works
CAF-induced physical constraints controlling T cell state and localization in solid tumours
Arpinati, L., Carradori, G., & Scherz‐Shouval, R. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00740-4 · Cited by 160 · see citing works
Meeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 149 · see citing works
Li, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 149 · see citing works
Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143 · see citing works
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma
Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 142 · see citing works
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
Jiang, H., Torphy, R. J., Steiger, K., Hongo, H., Ritchie, A. J., Kriegsmann, M., Horst, D., Umetsu, S. E., Joseph, N. M., McGregor, K., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136760 · Cited by 127 · see citing works
Yamamoto, Y., Kasashima, H., Fukui, Y., Tsujio, G., Yashiro, M., & Maeda, K. (2022) · Cancer Science · doi:10.1111/cas.15609 · Cited by 138 · see citing works
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 137 · see citing works
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
Chiaravalli, M., Reni, M., & O'Reilly, E. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.007 · Cited by 134 · see citing works
Regan, J. L., Schumacher, D., Staudte, S., Steffen, A., Haybaeck, J., Keilholz, U., Schweiger, C., Golob‐Schwarzl, N., Mumberg, D., Henderson, D. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.025 · Cited by 131 · see citing works
Gerling, M., Büller, N. V. J. A., Kirn, L. M., Joost, S., Frings, O., Englert, B., Bergström, Å., Kuiper, R., Blaas, L., Wielenga, M. C. B., et al. (2016) · Nature Communications · doi:10.1038/ncomms12321 · Cited by 129 · see citing works
Zhao, J., Wang, H., Hsiao, C.-H., Chow, D. S., Koay, E. J., Kang, Y., Wen, X., Huang, Q., Ma, Y., Bankson, J. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.014 · Cited by 128 · see citing works
Dzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 127 · see citing works
Hedgehog signaling inhibitors in solid and hematological cancers
Cortes, J. E., Gutzmer, R., Kieran, M. W., & Solomon, J. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.005 · Cited by 126 · see citing works
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 122 · see citing works
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 126 · see citing works
Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Liu, L., Kshirsagar, P., Gautam, S. K., Gulati, M., Wafa, E. I., Christiansen, J. C., White, B. M., Mallapragada, S. K., Wannemuehler, M. J., Sushil Kumar, K., et al. (2022) · Theranostics · doi:10.7150/thno.64805 · Cited by 124 · see citing works
Norton, J. A., Foster, D. S., Chinta, M. S., Titan, A. L., & Longaker, M. T. (2020) · Cancers · doi:10.3390/cancers12051347 · Cited by 124 · see citing works
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 126 · see citing works
From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts
Arpinati, L., & Scherz‐Shouval, R. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.01.007 · Cited by 127 · see citing works
LeSavage, B. L., Zhang, D. H., Huerta-López, C., Gilchrist, A. E., Krajina, B. A., Karlsson, K., Smith, A. R., Karagyozova, K., Klett, K. C., Huang, M. S., et al. (2024) · Nature Materials · doi:10.1038/s41563-024-01908-x · Cited by 138 · see citing works
Biological determinants of radioresistance and their remediation in pancreatic cancer
Seshacharyulu, P., Baine, M. J., Souchek, J. J., Menning, M., Kaur, S., Yan, Y., Ouellette, M. M., Jain, M., Lin, C. H., & Batra, S. K. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.003 · Cited by 123 · see citing works
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 124 · see citing works
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121 · see citing works
Self-citationCannon, A. C., Thompson, C. M., Hall, B. R., Jain, M., Sushil Kumar, K., & Batra, S. K. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.171 · Cited by 120 · see citing works
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 121 · see citing works
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 117 · see citing works
Antifibrotic therapy to normalize the tumor microenvironment
Hauge, A., & Rofstad, E. K. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02376-y · Cited by 115 · see citing works
- Authors
- Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., Cohen, D., Wade, J., Sleckman, B., Lenz, H.-J., Stiff, P., Kumar, P., Xu, P., Henderson, L., Takebe, N., Salgia, R., Wang, X., Stadler, W. M., de Sauvage, F. J., & Kindler, H. L.
- Affiliations
- Loyola University Medical Center (US)
- Daniel V.T. Catenacci, Theodore Karrison, James Wallace, Mark Kozloff, Peng Xu, Les Henderson, Ravi Salgia, Walter M. Stadler, Hedy L. Kindler, University of Chicago Medical Center; Patrick Stiff, Loyola University Medical Center, Chicago; Robert Marsh, Northshore University Health System, Evanston; James Wallace, Mark Kozloff, Ingalls Hospital, Harvey; James Wade, Decatur Memorial Hospital, Decatur; Pankaj Kumar, Oncology/Hematology Associates, Peoria, IL; Melissa R. Junttila, Xi Wang, and Frederic J....
- Corresponding author
- Catenacci, Daniel V.T.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-20
- Volume
- 33
- Issue
- 36
- Pages
- 4284-4292
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4678179
- OpenAlex
- W2137357003
- Cited by
- 561
- References
- 55
- Citations by year
- 2026: 40 · 2025: 36 · 2024: 38 · 2023: 47 · 2022: 71 · 2021: 72 · 2020: 67 · 2019: 65 · 2018: 60 · 2017: 41 · 2016: 20 · 2015: 3 · 2014: 1
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- European Society for Medical Oncology
- National Institutes of Health (UL1TR000430, n01cm62201-16-0-1)
- Genentech
- National Cancer Institute (N01 CM062201, N01 CM-62201)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metastatic pancreatic cancer, gemcitabine, vismodegib, sonic hedgehog pathway, Smoothened inhibition, Hedgehog pathway inhibitors, progression-free survival, overall survival, KRAS G12D, p53, drug safety, combination therapy
- MeSH terms
- Gemcitabine, Adult, Aged, Anilides, Animals, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Pyridines, Signal Transduction, Odds Ratio, Treatment Outcome, Karnofsky Performance Status, Disease-Free Survival, Mice, Kaplan-Meier Estimate, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
